Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment
Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment
复制标题
DOI：
10.1067/mob.2003.207
复制
发表时间：
2003-04-01
影响因子：
9.8
通讯作者：
Miner, CM
中科院分区：
文献类型：
--
作者：
Pearlstein, T;Joliat, MJ;Miner, CM
目的：本研究的目的是使用两项临床试验的数据，以评估经前焦虑障碍症状的严重程度后，氟西汀治疗的中止。研究设计：两项临床试验进行了回顾性分析。患者接受氟西汀或安慰剂治疗三个周期，使用几种不同的给药方案，然后单盲安慰剂治疗一个周期。复发的评估包括每日记录的严重程度的问题，希恩残疾量表，经前紧张量表，临床医生评定，和临床的全球印象severity.RESULTS：经前焦虑障碍症状显着增加氟西汀停药后。分数没有恢复到基线，但是，氟西汀组不再显着上级安慰剂。结论：这两项试验表明，经过三个周期的治疗，经前焦虑障碍症状复发后的第一个周期内停止治疗。症状的快速复发进一步支持经前焦虑障碍是一种不同于抑郁症的临床实体的观点。
OBJECTIVE:The aim of this study was to use the data from two clinical trials to evaluate premenstrual dysphoric disorder symptom severity after the discontinuation of fluoxetine treatment.STUDY DESIGN: A retrospective analysis of two clinical trials was performed. Patients were treated with fluoxetine or placebo for three cycles, with the use of several different dosing regimens, followed by single blind placebo treatment for one cycle. Assessments of relapse included the daily record of severity of problems, the Sheehan disability scale, the premenstrual tension scale-clinician rated, and the clinical global impressions-severity.RESULTS: Premenstrual dysphoric disorder symptoms significantly increased after fluoxetine discontinuation. The scores did not return to baseline; however, the fluoxetine group was no longer significantly superior to placebo.CONCLUSION: The two trials demonstrate that, after three cycles of treatment, premenstrual dysphoric disorder symptoms recur within the first cycle after treatment discontinuation. The rapid recurrence of symptoms further supports the view of premenstrual dysphoric disorder as a clinical entity distinct from depression.